P28 | Glecaprevir/pibrentasvir in HCV+ Lucanian patients

N. Buccianti¹, G. Zaccardo², M. Pace², N. Mecca², C. Vita², D. Ferrante², F. Coviello² | ¹UOC Medicina Interna, Azienda Ospedaliera San Carlo, Potenza, ²UOC Medicina Interna, Azienda Ospedaliera San Carlo, Potenza, Italy

Study Background and Purpose: The objective of our work is to demonstrate the therapeutic efficacy and safety of the all-genotype antiviral therapy (glecaprevir-pibrentasvir) (Maviret) in a cohort of 200 HCV-positive patients residing in the Basilicata region in real-life.
Materials and Methods: The enlistment period is between January 2020 and October 2023. The duration of treatment is 8 weeks (short-therapy). 200 patients were enrolled (110 M; 91 F). The genotypes found were: G1 93 (47%), G2 58 (29%), G3 41 (21%), G4 3 (4%). The degrees of fibrosis were assessed with Fibroscan (Echosens): F0 34 (17%), F1 60 (30%), F2 32 (16%), F3 25 (13%), F4 49 (25%).
Results: Sustained virological response (SVR) – undetectable viremia – is assessed at 12 weeks after the discontinuation of antiviral treatment in 100% of the treated population. Sustained virological response was not influenced by the degree of fibrosis, viremia, genotype, age, or sex. The safety of antiviral drugs was absolute (absence of adverse events).
Conclusions: The therapeutic efficacy and safety of the pangenotypic antiviral regimen (glecaprevir-pibrentasvir) are absolute even in real-life settings. Virus clearance can alter the natural history of chronic HCV-positive hepatitis, which over time is burdened by severe complications (ascites, hepatocellular carcinoma, hepatic metabolic decompensation) that reduce life expectancy.